###begin article-title 0
Perimembrane Aurora-A Expression is a Significant Prognostic Factor in Correlation with Proliferative Activity in Non-Small-Cell Lung Cancer (NSCLC)
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
Aurora-A, also known as STK15/BTAK, is a member of the protein serine/threonine kinase family, and experimental studies have revealed that Aurora-A plays critical roles in cell mitosis and in carcinogenesis. However, no clinical studies on Aurora-A expression in non-small-cell lung cancer (NSCLC) have been reported. Thus, the present study was conducted to assess the clinical significance of Aurora-A status.
###end p 2
###begin title 3
Experimental Design
###end title 3
###begin p 4
###xml 27 35 <span type="species:ncbi:9606">patients</span>
A total of 189 consecutive patients with resected pathologic (p-)stage I-IIIA, NSCLC were retrospectively reviewed, and immunohistochemical staining was used to detect Aurora-A expression.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 402 403 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
Aurora-A expression was negative in 31 patients (16.4%); among Aurora-A positive patients, 124 patients showed pure diffuse cytoplasmic Aurora-A expression and the other 34 patients showed perimembrane Aurora-A expression. Perimembrane Aurora-A tumors showed the highest proliferative index (PI) (mean PIs for negative, diffuse cytoplasmic, and perimembrane tumors: 49.2, 41.7, and 63.5, respectively; P < .001). Five-year survival rates of Aurora-A negative, diffuse cytoplasmic, and perimembrane patients were 67.8%, 66.7%, and 47.6%, respectively, showing the poorest postoperative survival in perimembrane patients (P = .033). Subset analyses revealed that perimembrane Aurora-A expression was a significant factor to predict a poor prognosis in squamous cell carcinoma patients, not in adenocarcinoma patients. A multivariate analysis confirmed that perimembrane Aurora-A expression was an independent and significant factor to predict a poor prognosis.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
Perimembrane Aurora-A status was a significant factor to predict a poor prognosis in correlation with enhanced proliferative activity in NSCLC.
###end p 8
###begin title 9
Keywords
###end title 9
###begin p 10
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 539 542 539 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k-ras</italic>
###xml 1190 1191 1190 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1192 1193 1192 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
Primary lung cancer is the leading cause of cancer deaths in most industrialized countries, and non-small-cell lung cancer (NSCLC) accounts for 75-80% of primary lung cancer. Surgery is the most effective therapeutic modality for the cure, but the postoperative prognosis remains poor.1-3 To improve the prognosis, establishment of biological markers other than tumor-node-metastasis (TNM) factors that determine prognosis and response to a particular treatment is essential. Although many possible biological markers such as mutations of p53 and k-ras genes have been reported, none of them has been established as a marker in decision-making of the treatment of NSCLC. In addition, most NSCLC patients present with advanced stages and are appropriate candidates for surgery. For inoperable patients, chemotherapy with or without radiotherapy may be given. Recently, tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR), gefitinib and erlotinib, have been introduced into the therapy of NSCLC, and experimental and clinical studies have revealed that these agents induce dramatic antitumor effects for tumors with activating mutations within the EGFR kinase domain.4,5 Thus, other molecular abnormalities in NSCLC should be revealed in the development of useful prognostic markers and in the development of effective molecular targeting agents.
###end p 10
###begin p 11
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 684 692 684 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aurora-A</italic>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1108 1110 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1111 1113 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1158 1160 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1361 1363 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1364 1366 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 1370 1372 1370 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1402 1404 1402 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
Aurora-A, also known as BTAK, STK15, Aurora-2, ARKI, or AIKI, is a member of the serine/threonine kinase family. As Aurora-A is involved in proper centrosome functions and chromosome segregation during normal cell mitosis,6-8 its abnormalities such as overexpression as well as gene amplification may contribute to development and progression of malignant tumors.9-11 In clinical studies, Aurora-A abnormalities have been reported in a variety of malignant tumor including glioma,12 medullobrastoma,13 gastric cancer,14 esophageal cancer,15,16 pancreatic cancer,17 ovarian cancer,18 breast cancer,19,20 bladder cancer,21 and hepatocellular carcinoma.22 In all these clinical studies, Aurora-A gene was amplified or Aurora-A expression was upregulated in tumor tissues compared with normal tissues, which also support experimental results suggesting that Aurora-A abnormalities are involved in carcinogenesis. In addition, many studies showed that Aurora-A abnormalities were positively correlated with aggressive tumor behavior such as poorly differentiated tumor grade, invasion, and nodal metastasis,15,16,19,20-22 but some studies showed no correlation12,17 or an inverse correlation.18 Some studies also assessed a prognostic significance of Aurora-A status; most studies showed that Aurora-A abnormalities were correlated with a significant poor prognosis,13,16,21,22 but one study failed to show.20 These results may suggest that clinical significant of Aurora-A status in malignant tumors remains controversial. Moreover, no clinical study on Aurora-A status in NSCLC has been reported. Thus, we conducted a clinical study on Aurora-A expression in resected NSCLC and assessed its clinical significance in correlation with other biomarkers including proliferative activity.
###end p 11
###begin title 12
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 13
###begin p 14
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 735 743 <span type="species:ncbi:9606">patients</span>
We retrospectively reviewed a total of 191 consecutive patients with pathologic (p)-stage I-IIIA NSCLC who underwent complete tumor resection and nodal dissection without any preoperative therapy at the Department of Thoracic Surgery, Kyoto University, between January 1, 1985 and December 31, 1990. The p-stage was reevaluated and determined according to the current tumor-node-metastasis (TNM) classification as revised in 1997.1 Histological type was also redetermined according to the classification by the World Health Organization (WHO) as revised in 2004. Two patients who experienced operation-related death were excluded from the study. Thus, a total of 189 patients were finally evaluated in the present study. For all these patients, the inpatient medical records, chest x-ray films, whole-body computed tomography (CT) films, bone and gallium scanning data, and records of surgery were reviewed without knowledge of the results of immunohistochemical staining (IHS) or the terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) staining.
###end p 14
###begin p 15
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 325 332 <span type="species:ncbi:9606">patient</span>
Details of postoperative adjuvant therapy were described in previous studies.23,24 In brief, cisplatin-based chemotherapy, radiation, and oral administration of tegafur (a fluorouracil derivative drug) were prescribed postoperatively for 47, 30, and 49 patients, respectively. Intraoperative therapy was not performed on any patient.
###end p 15
###begin p 16
The day of thoracotomy was considered the starting day for counting postoperative survival days. The median and mean follow-up periods were 1697 and 1983 days, respectively (range, 50-6381 days). This study has been approved by the Ethics Committee of Faculty of Medicine, Kyoto University.
###end p 16
###begin title 17
Tissue Preparation
###end title 17
###begin p 18
All tumor specimens were fixed immediately in 10 vol% formalin, and then embedded in paraffin. Serial 4-mum sections were prepared from each sample and used for routine hematoxylin and eosin (HE) staining, the TUNEL staining to detect apoptotic cells, and IHS to determine Aurora-A expression status, p53 status, intratumoral microvessel density (IMVD), and proliferative index (PI).
###end p 18
###begin title 19
Immunohistochemistry
###end title 19
###begin p 20
###xml 77 88 <span type="species:ncbi:3704">horseradish</span>
###xml 167 173 <span type="species:ncbi:9986">rabbit</span>
###xml 544 550 <span type="species:ncbi:9986">rabbit</span>
Aurora-A expression was evaluated using a standard streptavidin-biotinylated horseradish peroxidase detection system. Dewaxed sections were incubated overnight with a rabbit polyclonal antibody (KR051, Transgenic Co. Ltd., Kumamoto, Japan; it had been produced and its reliability had been confirmed by western blotting on a commercial basis) diluted at 1:100. Diaminobenzidine-tetrahydrochloride (0.03%) containing 0.1% hydrogen peroxide was used as a chromogen, and sections were counterstained with hematoxylin. For negative control slides, rabbit immunoglobulin G was used instead of the primary antibody. Colon cancer sections that are known to express Aurora-A were used as positive control slides.
###end p 20
###begin p 21
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 324 325 324 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 357 358 357 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 483 490 483 490 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1.</label>
###xml 593 594 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 614 615 614 615 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 646 647 646 647 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 490 671 490 671 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22">Aurora-A expression in non-small-cell carcinoma (NSCLC) as detected with imuunohistochemical staining. <bold>A</bold> Negative staining. <bold>B</bold> diffuse cytoplasmic staining. <bold>C</bold> Peri-membrane staining.</p>
###xml 490 671 490 671 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22">Aurora-A expression in non-small-cell carcinoma (NSCLC) as detected with imuunohistochemical staining. <bold>A</bold> Negative staining. <bold>B</bold> diffuse cytoplasmic staining. <bold>C</bold> Peri-membrane staining.</p></caption>
###xml 671 671 671 671 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9653_Fig1_HTML" id="MO1"/>
###xml 483 671 483 671 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1.</label><caption><p textid="22">Aurora-A expression in non-small-cell carcinoma (NSCLC) as detected with imuunohistochemical staining. <bold>A</bold> Negative staining. <bold>B</bold> diffuse cytoplasmic staining. <bold>C</bold> Peri-membrane staining.</p></caption><graphic position="anchor" xlink:href="10434_2007_9653_Fig1_HTML" id="MO1"/></fig>
###xml 459 466 <span type="species:ncbi:9606">patient</span>
Aurora-A expression on tumor cells was first classified into negative or positive expression; a slide was judged to be Aurora-A positive expression, regardless of the staining intensity. For slides with positive Aurora-A expression, the staining pattern was, then, classified as follows: diffuse cytoplasmic staining (Fig. 1B), perimembrane staining (Fig. 1C). Slides were evaluated by two pathologists (E.O. and Y.T.) independently, without knowledge of any patient characteristic. Fig. 1.Aurora-A expression in non-small-cell carcinoma (NSCLC) as detected with imuunohistochemical staining. A Negative staining. B diffuse cytoplasmic staining. C Peri-membrane staining.
###end p 21
###begin p 22
###xml 103 104 103 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 124 125 124 125 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 156 157 156 157 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
Aurora-A expression in non-small-cell carcinoma (NSCLC) as detected with imuunohistochemical staining. A Negative staining. B diffuse cytoplasmic staining. C Peri-membrane staining.
###end p 22
###begin p 23
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 871 873 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 135 140 <span type="species:ncbi:10090">mouse</span>
###xml 407 412 <span type="species:ncbi:10090">mouse</span>
###xml 674 679 <span type="species:ncbi:10090">mouse</span>
PI, IMVD, and p53 status were also determined with IHS as described previously.23,25 Briefly, an anti-PCNA monoclonal antibody (PC-10, mouse immunogloblin G [IgG] 2a, kappa; DAKO Japan, Kyoto, Japan) diluted at 1:50 was used as the primary antibody to determine PI;23 PI was defined as the percentage of PCNA-positive staining tumor cells. IMVD was determined with an anti-CD34 monoclonal antibody QBEnd10 (mouse IgG1, kappa; DAKO Japan) diluted at 1:50; the 10 most vascular areas within a section were selected for evaluation of angiogenesis, and the average counts of CD34-positive vessels were recorded as IMVD in each case.25 An antihuman p53 monoclonal antibody DO-7 (mouse IgG2b, kappa, 250 mug/mL, DAKO Japan) was used to determine p53 status. When the percentage of positive-staining cells exceeded 5%, the slide was judged to exhibit aberrant expression of p53.23
###end p 23
###begin title 24
Detection of Apoptosis
###end title 24
###begin p 25
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
The TUNEL staining was performed using the In Situ Death Detection Kit, POD (Boehringer Manheim, Manheim, Germany) following the manufacture's protocol as described previously.23 The specificity of the TUNEL staining of apoptotic cells was confirmed by making the negative and the positive control slides at every staining. As negative control slides, sections incubated with the TUNEL reaction mixture without TdT were used. Sections treated with DNase I (Stratagene, La Jolla, CA) before the TUNEL reaction were used as positive control slides. Apoptotic cells were determined with careful observation of TUNEL-staining sections and serial HE-staining sections, and TUNEL-positive staining cells, if they represented the histological features of necrosis in HE-staining sections, were not considered to be apoptotic cells. In each case, a total of 10,000 tumor cells, consisting of 1000 tumor cells each in 10 different fields, were evaluated at high magnification (400x). The apoptotic index (AI) was defined as the number of apoptotic cells per 1000 tumor cells.
###end p 25
###begin title 26
Statistical Analysis
###end title 26
###begin p 27
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 590 591 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Counts were compared by the chi-square test. Continuous data were compared using the t test if the distribution of the samples was normal, or using the Mann-Whitney U test if the sample distribution was asymmetrical. The postoperative survival rate was analyzed by the Kaplan-Meier method, and differences in the survival rates were assessed by the log-rank test. Death from any cause was included in calculation of postoperative survival. Multivariate analysis of the prognostic factors was performed using Cox's proportional hazard model. Differences were considered significant when the P value was less than .05. All statistical manipulations were performed using the SPSS ver.10 for the Windows software system (SPSS Inc., Chicago, IL).
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
Expression of Aurora-A in NSCLC
###end title 29
###begin p 30
###xml 514 515 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 778 779 778 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 782 790 782 790 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1.</label>
###xml 790 839 790 839 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Characteristics of patients and Aurora expression</p>
###xml 790 839 790 839 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Characteristics of patients and Aurora expression</p></caption>
###xml 839 839 839 839 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"/>
###xml 839 858 839 858 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">No. of patients (%)</th>
###xml 858 876 858 876 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">MAGE-D4 expression</th>
###xml 876 877 876 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 876 883 876 883 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"><italic>P</italic> value</th>
###xml 839 883 839 883 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3"/><th align="left" rowspan="3">No. of patients (%)</th><th align="left" colspan="3">MAGE-D4 expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr>
###xml 883 891 883 891 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Negative</th>
###xml 891 899 891 899 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Positive</th>
###xml 883 899 883 899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr>
###xml 899 918 899 918 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diffuse cytoplasmic</th>
###xml 918 930 918 930 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Perimembrane</th>
###xml 899 930 899 930 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr>
###xml 839 930 839 930 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3"/><th align="left" rowspan="3">No. of patients (%)</th><th align="left" colspan="3">MAGE-D4 expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead>
###xml 930 942 930 942 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All patients</td>
###xml 942 951 942 951 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">189 (100)</td>
###xml 951 961 951 961 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">31 (16.4%)</td>
###xml 961 972 961 972 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">124 (65.6%)</td>
###xml 972 982 972 982 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">34 (18.0%)</td>
###xml 982 982 982 982 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 930 982 930 982 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">All patients</td><td align="left">189 (100)</td><td align="left">31 (16.4%)</td><td align="left">124 (65.6%)</td><td align="left">34 (18.0%)</td><td align="left"/></tr>
###xml 982 1012 982 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (mean&#160;&#177;&#160;SD) 62.4&#160;&#177;&#160;9.6</td>
###xml 1012 1025 1008 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60.5&#160;&#177;&#160;10.2</td>
###xml 1025 1037 1019 1029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">62.3&#160;&#177;&#160;9.2</td>
###xml 1037 1049 1029 1039 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64.3&#160;&#177;&#160;9.1</td>
###xml 1049 1054 1039 1044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.256</td>
###xml 1054 1054 1044 1044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 982 1054 982 1044 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age (mean&#160;&#177;&#160;SD) 62.4&#160;&#177;&#160;9.6</td><td align="left">60.5&#160;&#177;&#160;10.2</td><td align="left">62.3&#160;&#177;&#160;9.2</td><td align="left">64.3&#160;&#177;&#160;9.1</td><td align="left">0.256</td><td align="left"/></tr>
###xml 1054 1057 1044 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sex</td>
###xml 1057 1057 1047 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1057 1057 1047 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1057 1057 1047 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1057 1057 1047 1047 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1057 1061 1047 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">.137</td>
###xml 1054 1061 1044 1051 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.137</td></tr>
###xml 1061 1069 1051 1059 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Male</td>
###xml 1069 1079 1059 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">133 (70.4)</td>
###xml 1079 1089 1069 1079 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26 (19.5%)</td>
###xml 1089 1099 1079 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">86 (64.7%)</td>
###xml 1099 1109 1089 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21 (15.8%)</td>
###xml 1109 1109 1099 1099 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1061 1109 1051 1099 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Male</td><td align="left">133 (70.4)</td><td align="left">26 (19.5%)</td><td align="left">86 (64.7%)</td><td align="left">21 (15.8%)</td><td align="left"/></tr>
###xml 1109 1119 1099 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Female</td>
###xml 1119 1128 1109 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">56 (29.6)</td>
###xml 1128 1136 1118 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5 (8.9%)</td>
###xml 1136 1146 1126 1136 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38 (67.9%)</td>
###xml 1146 1156 1136 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13 (23.2%)</td>
###xml 1156 1156 1146 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1109 1156 1099 1146 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Female</td><td align="left">56 (29.6)</td><td align="left">5 (8.9%)</td><td align="left">38 (67.9%)</td><td align="left">13 (23.2%)</td><td align="left"/></tr>
###xml 1156 1179 1146 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Performance status (PS)</td>
###xml 1179 1179 1169 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1179 1179 1169 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1179 1179 1169 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1179 1179 1169 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1179 1183 1169 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">.353</td>
###xml 1156 1183 1146 1173 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Performance status (PS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.353</td></tr>
###xml 1183 1188 1173 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;0</td>
###xml 1188 1198 1178 1188 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">164 (86.8)</td>
###xml 1198 1208 1188 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">28 (17.1%)</td>
###xml 1208 1219 1198 1209 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">109 (66.5%)</td>
###xml 1219 1229 1209 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">27 (16.5%)</td>
###xml 1229 1229 1219 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1183 1229 1173 1219 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;0</td><td align="left">164 (86.8)</td><td align="left">28 (17.1%)</td><td align="left">109 (66.5%)</td><td align="left">27 (16.5%)</td><td align="left"/></tr>
###xml 1229 1236 1219 1226 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;1&#8211;2</td>
###xml 1236 1245 1226 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25 (13.2)</td>
###xml 1245 1254 1235 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3 (12.0%)</td>
###xml 1254 1264 1244 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (60.0%)</td>
###xml 1264 1273 1254 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (28.0%)</td>
###xml 1273 1273 1263 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1229 1273 1219 1263 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;1&#8211;2</td><td align="left">25 (13.2)</td><td align="left">3 (12.0%)</td><td align="left">15 (60.0%)</td><td align="left">7 (28.0%)</td><td align="left"/></tr>
###xml 1273 1288 1263 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Histologic type</td>
###xml 1288 1288 1278 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1288 1288 1278 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1288 1288 1278 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1288 1288 1278 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1288 1303 1278 1293 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">.302 (Sq vs Ad)</td>
###xml 1273 1303 1263 1293 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Histologic type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.302 (Sq vs Ad)</td></tr>
###xml 1303 1325 1293 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td>
###xml 1325 1334 1315 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">64 (33.9)</td>
###xml 1334 1343 1324 1333 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8 (12.5%)</td>
###xml 1343 1353 1333 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">41 (64.1%)</td>
###xml 1353 1363 1343 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (23.4%)</td>
###xml 1363 1363 1353 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1303 1363 1293 1353 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td align="left">64 (33.9)</td><td align="left">8 (12.5%)</td><td align="left">41 (64.1%)</td><td align="left">15 (23.4%)</td><td align="left"/></tr>
###xml 1363 1377 1353 1367 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td>
###xml 1377 1387 1367 1377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">108 (57.1)</td>
###xml 1387 1397 1377 1387 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">19 (17.6%)</td>
###xml 1397 1407 1387 1397 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">73 (67.6%)</td>
###xml 1407 1417 1397 1407 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16 (14.8%)</td>
###xml 1417 1417 1407 1407 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1363 1417 1353 1407 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td align="left">108 (57.1)</td><td align="left">19 (17.6%)</td><td align="left">73 (67.6%)</td><td align="left">16 (14.8%)</td><td align="left"/></tr>
###xml 1417 1436 1407 1426 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Large cell (La)</td>
###xml 1436 1444 1426 1434 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (5.3)</td>
###xml 1444 1453 1434 1443 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (40.0%)</td>
###xml 1453 1462 1443 1452 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (40.0%)</td>
###xml 1462 1471 1452 1461 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (20.0%)</td>
###xml 1471 1471 1461 1461 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1417 1471 1407 1461 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Large cell (La)</td><td align="left">10 (5.3)</td><td align="left">4 (40.0%)</td><td align="left">4 (40.0%)</td><td align="left">2 (20.0%)</td><td align="left"/></tr>
###xml 1471 1481 1461 1471 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Others</td>
###xml 1481 1488 1471 1478 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (3.7)</td>
###xml 1488 1496 1478 1486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0.0%)</td>
###xml 1496 1505 1486 1495 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5 (85.7%)</td>
###xml 1505 1514 1495 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1 (14.3%)</td>
###xml 1514 1514 1504 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1471 1514 1461 1504 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Others</td><td align="left">7 (3.7)</td><td align="left">0 (0.0%)</td><td align="left">5 (85.7%)</td><td align="left">1 (14.3%)</td><td align="left"/></tr>
###xml 1535 1536 1525 1526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1514 1536 1504 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tumor differentiation<sup>*</sup></td>
###xml 1536 1536 1526 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1536 1536 1526 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1536 1536 1526 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1536 1536 1526 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1536 1540 1526 1530 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">.393</td>
###xml 1514 1540 1504 1530 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tumor differentiation<sup>*</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.393</td></tr>
###xml 1540 1548 1530 1538 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Well</td>
###xml 1548 1557 1538 1547 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">68 (37.4)</td>
###xml 1557 1566 1547 1556 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9 (13.2%)</td>
###xml 1566 1576 1556 1566 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49 (72.1%)</td>
###xml 1576 1586 1566 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10 (14.7%)</td>
###xml 1586 1586 1576 1576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1540 1586 1530 1576 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Well</td><td align="left">68 (37.4)</td><td align="left">9 (13.2%)</td><td align="left">49 (72.1%)</td><td align="left">10 (14.7%)</td><td align="left"/></tr>
###xml 1586 1600 1576 1590 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Moderately</td>
###xml 1600 1609 1590 1599 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">67 (36.8)</td>
###xml 1609 1619 1599 1609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13 (19.4%)</td>
###xml 1619 1629 1609 1619 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">43 (64.2%)</td>
###xml 1629 1639 1619 1629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11 (16.4%)</td>
###xml 1639 1639 1629 1629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1586 1639 1576 1629 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Moderately</td><td align="left">67 (36.8)</td><td align="left">13 (19.4%)</td><td align="left">43 (64.2%)</td><td align="left">11 (16.4%)</td><td align="left"/></tr>
###xml 1639 1649 1629 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Poorly</td>
###xml 1649 1658 1639 1648 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">47 (25.8)</td>
###xml 1658 1667 1648 1657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9 (19.1%)</td>
###xml 1667 1677 1657 1667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26 (55.3%)</td>
###xml 1677 1687 1667 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (25.5%)</td>
###xml 1687 1687 1677 1677 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1639 1687 1629 1677 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Poorly</td><td align="left">47 (25.8)</td><td align="left">9 (19.1%)</td><td align="left">26 (55.3%)</td><td align="left">12 (25.5%)</td><td align="left"/></tr>
###xml 1687 1708 1677 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pathologic (p-) stage</td>
###xml 1708 1708 1698 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1708 1708 1698 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1708 1708 1698 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1708 1708 1698 1698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1708 1730 1698 1720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">.007 (for all p-stage)</td>
###xml 1687 1730 1677 1720 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Pathologic (p-) stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.007 (for all p-stage)</td></tr>
###xml 1730 1735 1720 1725 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;I</td>
###xml 1735 1745 1725 1735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">104 (55.0)</td>
###xml 1745 1755 1735 1745 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (11.5%)</td>
###xml 1755 1765 1745 1755 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">80 (76.9%)</td>
###xml 1765 1775 1755 1765 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (11.5%)</td>
###xml 1775 1775 1765 1765 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1730 1775 1720 1765 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;I</td><td align="left">104 (55.0)</td><td align="left">12 (11.5%)</td><td align="left">80 (76.9%)</td><td align="left">12 (11.5%)</td><td align="left"/></tr>
###xml 1775 1781 1765 1771 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;II</td>
###xml 1781 1790 1771 1780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">22 (11.6)</td>
###xml 1790 1799 1780 1789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (18.2%)</td>
###xml 1799 1809 1789 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11 (50.0%)</td>
###xml 1809 1818 1799 1808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7 (31.8%)</td>
###xml 1818 1818 1808 1808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1775 1818 1765 1808 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;II</td><td align="left">22 (11.6)</td><td align="left">4 (18.2%)</td><td align="left">11 (50.0%)</td><td align="left">7 (31.8%)</td><td align="left"/></tr>
###xml 1818 1826 1808 1816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;IIIA</td>
###xml 1826 1835 1816 1825 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">63 (33.3)</td>
###xml 1835 1845 1825 1835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (23.8%)</td>
###xml 1845 1855 1835 1845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33 (52.4%)</td>
###xml 1855 1865 1845 1855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15 (23.8%)</td>
###xml 1865 1865 1855 1855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1818 1865 1808 1855 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td align="left">63 (33.3)</td><td align="left">15 (23.8%)</td><td align="left">33 (52.4%)</td><td align="left">15 (23.8%)</td><td align="left"/></tr>
###xml 930 1865 930 1855 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">All patients</td><td align="left">189 (100)</td><td align="left">31 (16.4%)</td><td align="left">124 (65.6%)</td><td align="left">34 (18.0%)</td><td align="left"/></tr><tr><td align="left">Age (mean&#160;&#177;&#160;SD) 62.4&#160;&#177;&#160;9.6</td><td align="left">60.5&#160;&#177;&#160;10.2</td><td align="left">62.3&#160;&#177;&#160;9.2</td><td align="left">64.3&#160;&#177;&#160;9.1</td><td align="left">0.256</td><td align="left"/></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.137</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Male</td><td align="left">133 (70.4)</td><td align="left">26 (19.5%)</td><td align="left">86 (64.7%)</td><td align="left">21 (15.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Female</td><td align="left">56 (29.6)</td><td align="left">5 (8.9%)</td><td align="left">38 (67.9%)</td><td align="left">13 (23.2%)</td><td align="left"/></tr><tr><td align="left">Performance status (PS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.353</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;0</td><td align="left">164 (86.8)</td><td align="left">28 (17.1%)</td><td align="left">109 (66.5%)</td><td align="left">27 (16.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;1&#8211;2</td><td align="left">25 (13.2)</td><td align="left">3 (12.0%)</td><td align="left">15 (60.0%)</td><td align="left">7 (28.0%)</td><td align="left"/></tr><tr><td align="left">Histologic type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.302 (Sq vs Ad)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td align="left">64 (33.9)</td><td align="left">8 (12.5%)</td><td align="left">41 (64.1%)</td><td align="left">15 (23.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td align="left">108 (57.1)</td><td align="left">19 (17.6%)</td><td align="left">73 (67.6%)</td><td align="left">16 (14.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Large cell (La)</td><td align="left">10 (5.3)</td><td align="left">4 (40.0%)</td><td align="left">4 (40.0%)</td><td align="left">2 (20.0%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Others</td><td align="left">7 (3.7)</td><td align="left">0 (0.0%)</td><td align="left">5 (85.7%)</td><td align="left">1 (14.3%)</td><td align="left"/></tr><tr><td align="left">Tumor differentiation<sup>*</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.393</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Well</td><td align="left">68 (37.4)</td><td align="left">9 (13.2%)</td><td align="left">49 (72.1%)</td><td align="left">10 (14.7%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Moderately</td><td align="left">67 (36.8)</td><td align="left">13 (19.4%)</td><td align="left">43 (64.2%)</td><td align="left">11 (16.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Poorly</td><td align="left">47 (25.8)</td><td align="left">9 (19.1%)</td><td align="left">26 (55.3%)</td><td align="left">12 (25.5%)</td><td align="left"/></tr><tr><td align="left">Pathologic (p-) stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.007 (for all p-stage)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td align="left">104 (55.0)</td><td align="left">12 (11.5%)</td><td align="left">80 (76.9%)</td><td align="left">12 (11.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td align="left">22 (11.6)</td><td align="left">4 (18.2%)</td><td align="left">11 (50.0%)</td><td align="left">7 (31.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td align="left">63 (33.3)</td><td align="left">15 (23.8%)</td><td align="left">33 (52.4%)</td><td align="left">15 (23.8%)</td><td align="left"/></tr></tbody>
###xml 839 1865 839 1855 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="3">No. of patients (%)</th><th align="left" colspan="3">MAGE-D4 expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">All patients</td><td align="left">189 (100)</td><td align="left">31 (16.4%)</td><td align="left">124 (65.6%)</td><td align="left">34 (18.0%)</td><td align="left"/></tr><tr><td align="left">Age (mean&#160;&#177;&#160;SD) 62.4&#160;&#177;&#160;9.6</td><td align="left">60.5&#160;&#177;&#160;10.2</td><td align="left">62.3&#160;&#177;&#160;9.2</td><td align="left">64.3&#160;&#177;&#160;9.1</td><td align="left">0.256</td><td align="left"/></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.137</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Male</td><td align="left">133 (70.4)</td><td align="left">26 (19.5%)</td><td align="left">86 (64.7%)</td><td align="left">21 (15.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Female</td><td align="left">56 (29.6)</td><td align="left">5 (8.9%)</td><td align="left">38 (67.9%)</td><td align="left">13 (23.2%)</td><td align="left"/></tr><tr><td align="left">Performance status (PS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.353</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;0</td><td align="left">164 (86.8)</td><td align="left">28 (17.1%)</td><td align="left">109 (66.5%)</td><td align="left">27 (16.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;1&#8211;2</td><td align="left">25 (13.2)</td><td align="left">3 (12.0%)</td><td align="left">15 (60.0%)</td><td align="left">7 (28.0%)</td><td align="left"/></tr><tr><td align="left">Histologic type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.302 (Sq vs Ad)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td align="left">64 (33.9)</td><td align="left">8 (12.5%)</td><td align="left">41 (64.1%)</td><td align="left">15 (23.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td align="left">108 (57.1)</td><td align="left">19 (17.6%)</td><td align="left">73 (67.6%)</td><td align="left">16 (14.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Large cell (La)</td><td align="left">10 (5.3)</td><td align="left">4 (40.0%)</td><td align="left">4 (40.0%)</td><td align="left">2 (20.0%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Others</td><td align="left">7 (3.7)</td><td align="left">0 (0.0%)</td><td align="left">5 (85.7%)</td><td align="left">1 (14.3%)</td><td align="left"/></tr><tr><td align="left">Tumor differentiation<sup>*</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.393</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Well</td><td align="left">68 (37.4)</td><td align="left">9 (13.2%)</td><td align="left">49 (72.1%)</td><td align="left">10 (14.7%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Moderately</td><td align="left">67 (36.8)</td><td align="left">13 (19.4%)</td><td align="left">43 (64.2%)</td><td align="left">11 (16.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Poorly</td><td align="left">47 (25.8)</td><td align="left">9 (19.1%)</td><td align="left">26 (55.3%)</td><td align="left">12 (25.5%)</td><td align="left"/></tr><tr><td align="left">Pathologic (p-) stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.007 (for all p-stage)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td align="left">104 (55.0)</td><td align="left">12 (11.5%)</td><td align="left">80 (76.9%)</td><td align="left">12 (11.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td align="left">22 (11.6)</td><td align="left">4 (18.2%)</td><td align="left">11 (50.0%)</td><td align="left">7 (31.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td align="left">63 (33.3)</td><td align="left">15 (23.8%)</td><td align="left">33 (52.4%)</td><td align="left">15 (23.8%)</td><td align="left"/></tr></tbody></table>
###xml 1865 1866 1855 1856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 1865 1920 1855 1910 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32"><sup>*</sup>&#160;Other histologic types were excluded in the analyses.</p>
###xml 1865 1920 1855 1910 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32"><sup>*</sup>&#160;Other histologic types were excluded in the analyses.</p></table-wrap-foot>
###xml 782 1920 782 1910 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1.</label><caption><p textid="31">Characteristics of patients and Aurora expression</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="3">No. of patients (%)</th><th align="left" colspan="3">MAGE-D4 expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">All patients</td><td align="left">189 (100)</td><td align="left">31 (16.4%)</td><td align="left">124 (65.6%)</td><td align="left">34 (18.0%)</td><td align="left"/></tr><tr><td align="left">Age (mean&#160;&#177;&#160;SD) 62.4&#160;&#177;&#160;9.6</td><td align="left">60.5&#160;&#177;&#160;10.2</td><td align="left">62.3&#160;&#177;&#160;9.2</td><td align="left">64.3&#160;&#177;&#160;9.1</td><td align="left">0.256</td><td align="left"/></tr><tr><td align="left">Sex</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.137</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Male</td><td align="left">133 (70.4)</td><td align="left">26 (19.5%)</td><td align="left">86 (64.7%)</td><td align="left">21 (15.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Female</td><td align="left">56 (29.6)</td><td align="left">5 (8.9%)</td><td align="left">38 (67.9%)</td><td align="left">13 (23.2%)</td><td align="left"/></tr><tr><td align="left">Performance status (PS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.353</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;0</td><td align="left">164 (86.8)</td><td align="left">28 (17.1%)</td><td align="left">109 (66.5%)</td><td align="left">27 (16.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;1&#8211;2</td><td align="left">25 (13.2)</td><td align="left">3 (12.0%)</td><td align="left">15 (60.0%)</td><td align="left">7 (28.0%)</td><td align="left"/></tr><tr><td align="left">Histologic type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.302 (Sq vs Ad)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td align="left">64 (33.9)</td><td align="left">8 (12.5%)</td><td align="left">41 (64.1%)</td><td align="left">15 (23.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td align="left">108 (57.1)</td><td align="left">19 (17.6%)</td><td align="left">73 (67.6%)</td><td align="left">16 (14.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Large cell (La)</td><td align="left">10 (5.3)</td><td align="left">4 (40.0%)</td><td align="left">4 (40.0%)</td><td align="left">2 (20.0%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Others</td><td align="left">7 (3.7)</td><td align="left">0 (0.0%)</td><td align="left">5 (85.7%)</td><td align="left">1 (14.3%)</td><td align="left"/></tr><tr><td align="left">Tumor differentiation<sup>*</sup></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.393</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Well</td><td align="left">68 (37.4)</td><td align="left">9 (13.2%)</td><td align="left">49 (72.1%)</td><td align="left">10 (14.7%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Moderately</td><td align="left">67 (36.8)</td><td align="left">13 (19.4%)</td><td align="left">43 (64.2%)</td><td align="left">11 (16.4%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;Poorly</td><td align="left">47 (25.8)</td><td align="left">9 (19.1%)</td><td align="left">26 (55.3%)</td><td align="left">12 (25.5%)</td><td align="left"/></tr><tr><td align="left">Pathologic (p-) stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">.007 (for all p-stage)</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td align="left">104 (55.0)</td><td align="left">12 (11.5%)</td><td align="left">80 (76.9%)</td><td align="left">12 (11.5%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td align="left">22 (11.6)</td><td align="left">4 (18.2%)</td><td align="left">11 (50.0%)</td><td align="left">7 (31.8%)</td><td align="left"/></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td align="left">63 (33.3)</td><td align="left">15 (23.8%)</td><td align="left">33 (52.4%)</td><td align="left">15 (23.8%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p textid="32"><sup>*</sup>&#160;Other histologic types were excluded in the analyses.</p></table-wrap-foot></table-wrap>
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 454 462 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
###xml 716 724 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
###xml 809 817 <span type="species:ncbi:9606">patients</span>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
Expression of Aurora-A was not observed in normal adjacent lung tissues in any patient. Expression of Aurora-A in tumor cells was negative in 31 patients (16.4%) and positive in the other158 patients. Among Aurora-A positive patients, 124 patients showed diffuse cytoplasmic staining, 6 patients showed pure perimembrane staining, and 28 patients showed both diffuse cytoplasmic staining and perimembrane staining (mixed staining). Because the number of patients showing pure perimembrane staining was very small (n = 6), both patients with pure perimembrane staining and patients with mixed staining were classified into perimembrane patients. Thus, there were 31 negative patients (16.4%), 124 diffuse cytoplasmic patients (65.6%), and 34 perimembrane patients (18.0%) (Table 1). Table 1.Characteristics of patients and Aurora expressionNo. of patients (%)MAGE-D4 expressionP valueNegativePositiveDiffuse cytoplasmicPerimembraneAll patients189 (100)31 (16.4%)124 (65.6%)34 (18.0%)Age (mean +/- SD) 62.4 +/- 9.660.5 +/- 10.262.3 +/- 9.264.3 +/- 9.10.256Sex.137    Male133 (70.4)26 (19.5%)86 (64.7%)21 (15.8%)    Female56 (29.6)5 (8.9%)38 (67.9%)13 (23.2%)Performance status (PS).353    0164 (86.8)28 (17.1%)109 (66.5%)27 (16.5%)    1-225 (13.2)3 (12.0%)15 (60.0%)7 (28.0%)Histologic type.302 (Sq vs Ad)    Squamous cell (Sq)64 (33.9)8 (12.5%)41 (64.1%)15 (23.4%)    Adeno (Ad)108 (57.1)19 (17.6%)73 (67.6%)16 (14.8%)    Large cell (La)10 (5.3)4 (40.0%)4 (40.0%)2 (20.0%)    Others7 (3.7)0 (0.0%)5 (85.7%)1 (14.3%)Tumor differentiation*.393    Well68 (37.4)9 (13.2%)49 (72.1%)10 (14.7%)    Moderately67 (36.8)13 (19.4%)43 (64.2%)11 (16.4%)    Poorly47 (25.8)9 (19.1%)26 (55.3%)12 (25.5%)Pathologic (p-) stage.007 (for all p-stage)    I104 (55.0)12 (11.5%)80 (76.9%)12 (11.5%)    II22 (11.6)4 (18.2%)11 (50.0%)7 (31.8%)    IIIA63 (33.3)15 (23.8%)33 (52.4%)15 (23.8%)* Other histologic types were excluded in the analyses.
###end p 30
###begin p 31
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Characteristics of patients and Aurora expression
###end p 31
###begin p 32
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* Other histologic types were excluded in the analyses.
###end p 32
###begin p 33
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
The incidence of perimembrane staining was significantly higher in higher p-stages; perimembrane staining was seen in only 11.5% (12 of 104) of p-stage I patients, but seen in as high as 25.8% (22 of 85) of p-stage II-IIIA patients (Table 1). There was no significant correlation between Aurora-A expression status and any other patients' characteristic (Table 1).
###end p 33
###begin p 34
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 467 475 467 475 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2.</label>
###xml 475 533 475 533 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Correlation between Aurora expression and other biomarkers</p>
###xml 475 533 475 533 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Correlation between Aurora expression and other biomarkers</p></caption>
###xml 533 533 533 533 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"/>
###xml 533 550 533 550 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Aurora expression</th>
###xml 550 551 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 550 557 550 557 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"><italic>P</italic> value</th>
###xml 533 557 533 557 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3"/><th align="left" colspan="3">Aurora expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr>
###xml 557 565 557 565 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Negative</th>
###xml 565 573 565 573 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Positive</th>
###xml 557 573 557 573 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr>
###xml 573 592 573 592 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diffuse cytoplasmic</th>
###xml 592 604 592 604 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Perimembrane</th>
###xml 573 604 573 604 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr>
###xml 533 604 533 604 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3"/><th align="left" colspan="3">Aurora expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 604 644 604 644 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Intratumoral microvessel density (IMVD)<sup>*</sup></td>
###xml 644 658 644 656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">191.2&#160;&#177;&#160;16.3</td>
###xml 658 671 656 667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">174.7&#160;&#177;&#160;8.9</td>
###xml 671 685 667 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">167.6&#160;&#177;&#160;14.6</td>
###xml 685 689 679 683 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.584</td>
###xml 604 689 604 683 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Intratumoral microvessel density (IMVD)<sup>*</sup></td><td align="left">191.2&#160;&#177;&#160;16.3</td><td align="left">174.7&#160;&#177;&#160;8.9</td><td align="left">167.6&#160;&#177;&#160;14.6</td><td char="." align="char">.584</td></tr>
###xml 689 717 683 711 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Proliferative index (PI) (%)</td>
###xml 717 729 711 721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">49.2&#160;&#177;&#160;4.8</td>
###xml 729 741 721 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">41.7&#160;&#177;&#160;2.5</td>
###xml 741 753 731 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">63.5&#160;&#177;&#160;3.8</td>
###xml 753 758 741 746 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;.001</td>
###xml 689 758 683 746 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Proliferative index (PI) (%)</td><td align="left">49.2&#160;&#177;&#160;4.8</td><td align="left">41.7&#160;&#177;&#160;2.5</td><td align="left">63.5&#160;&#177;&#160;3.8</td><td char="." align="char">&lt;.001</td></tr>
###xml 758 798 746 786 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Apoptotic index (AI) (/1000 tumor cells)</td>
###xml 798 810 786 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13.5&#160;&#177;&#160;3.2</td>
###xml 810 822 796 806 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">20.5&#160;&#177;&#160;2.0</td>
###xml 822 834 806 816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15.9&#160;&#177;&#160;2.5</td>
###xml 834 838 816 820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.154</td>
###xml 758 838 746 820 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Apoptotic index (AI) (/1000 tumor cells)</td><td align="left">13.5&#160;&#177;&#160;3.2</td><td align="left">20.5&#160;&#177;&#160;2.0</td><td align="left">15.9&#160;&#177;&#160;2.5</td><td char="." align="char">.154</td></tr>
###xml 838 873 820 855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">p53-status: Aberrant expression (+)</td>
###xml 873 886 855 868 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12/31 (38.7%)</td>
###xml 886 900 868 882 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">55/124 (44.4%)</td>
###xml 900 913 882 895 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15/34 (44.1%)</td>
###xml 913 917 895 899 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.848</td>
###xml 838 917 820 899 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">p53-status: Aberrant expression (+)</td><td align="left">12/31 (38.7%)</td><td align="left">55/124 (44.4%)</td><td align="left">15/34 (44.1%)</td><td char="." align="char">.848</td></tr>
###xml 604 917 604 899 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Intratumoral microvessel density (IMVD)<sup>*</sup></td><td align="left">191.2&#160;&#177;&#160;16.3</td><td align="left">174.7&#160;&#177;&#160;8.9</td><td align="left">167.6&#160;&#177;&#160;14.6</td><td char="." align="char">.584</td></tr><tr><td align="left">Proliferative index (PI) (%)</td><td align="left">49.2&#160;&#177;&#160;4.8</td><td align="left">41.7&#160;&#177;&#160;2.5</td><td align="left">63.5&#160;&#177;&#160;3.8</td><td char="." align="char">&lt;.001</td></tr><tr><td align="left">Apoptotic index (AI) (/1000 tumor cells)</td><td align="left">13.5&#160;&#177;&#160;3.2</td><td align="left">20.5&#160;&#177;&#160;2.0</td><td align="left">15.9&#160;&#177;&#160;2.5</td><td char="." align="char">.154</td></tr><tr><td align="left">p53-status: Aberrant expression (+)</td><td align="left">12/31 (38.7%)</td><td align="left">55/124 (44.4%)</td><td align="left">15/34 (44.1%)</td><td char="." align="char">.848</td></tr></tbody>
###xml 533 917 533 899 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="3">Aurora expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">Intratumoral microvessel density (IMVD)<sup>*</sup></td><td align="left">191.2&#160;&#177;&#160;16.3</td><td align="left">174.7&#160;&#177;&#160;8.9</td><td align="left">167.6&#160;&#177;&#160;14.6</td><td char="." align="char">.584</td></tr><tr><td align="left">Proliferative index (PI) (%)</td><td align="left">49.2&#160;&#177;&#160;4.8</td><td align="left">41.7&#160;&#177;&#160;2.5</td><td align="left">63.5&#160;&#177;&#160;3.8</td><td char="." align="char">&lt;.001</td></tr><tr><td align="left">Apoptotic index (AI) (/1000 tumor cells)</td><td align="left">13.5&#160;&#177;&#160;3.2</td><td align="left">20.5&#160;&#177;&#160;2.0</td><td align="left">15.9&#160;&#177;&#160;2.5</td><td char="." align="char">.154</td></tr><tr><td align="left">p53-status: Aberrant expression (+)</td><td align="left">12/31 (38.7%)</td><td align="left">55/124 (44.4%)</td><td align="left">15/34 (44.1%)</td><td char="." align="char">.848</td></tr></tbody></table>
###xml 917 971 899 951 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">Values were shown as the mean&#160;&#177;&#160;standard error (SE).</p>
###xml 971 972 951 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
###xml 971 1010 951 990 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><sup>*</sup>&#160;Evaluated with an anti-CD34 antibody.</p>
###xml 917 1010 899 990 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">Values were shown as the mean&#160;&#177;&#160;standard error (SE).</p><p textid="37"><sup>*</sup>&#160;Evaluated with an anti-CD34 antibody.</p></table-wrap-foot>
###xml 467 1010 467 990 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2.</label><caption><p textid="35">Correlation between Aurora expression and other biomarkers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="3">Aurora expression</th><th align="left" rowspan="3"><italic>P</italic> value</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">Intratumoral microvessel density (IMVD)<sup>*</sup></td><td align="left">191.2&#160;&#177;&#160;16.3</td><td align="left">174.7&#160;&#177;&#160;8.9</td><td align="left">167.6&#160;&#177;&#160;14.6</td><td char="." align="char">.584</td></tr><tr><td align="left">Proliferative index (PI) (%)</td><td align="left">49.2&#160;&#177;&#160;4.8</td><td align="left">41.7&#160;&#177;&#160;2.5</td><td align="left">63.5&#160;&#177;&#160;3.8</td><td char="." align="char">&lt;.001</td></tr><tr><td align="left">Apoptotic index (AI) (/1000 tumor cells)</td><td align="left">13.5&#160;&#177;&#160;3.2</td><td align="left">20.5&#160;&#177;&#160;2.0</td><td align="left">15.9&#160;&#177;&#160;2.5</td><td char="." align="char">.154</td></tr><tr><td align="left">p53-status: Aberrant expression (+)</td><td align="left">12/31 (38.7%)</td><td align="left">55/124 (44.4%)</td><td align="left">15/34 (44.1%)</td><td char="." align="char">.848</td></tr></tbody></table><table-wrap-foot><p textid="36">Values were shown as the mean&#160;&#177;&#160;standard error (SE).</p><p textid="37"><sup>*</sup>&#160;Evaluated with an anti-CD34 antibody.</p></table-wrap-foot></table-wrap>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
The mean PI for perimembrane Aurora-A expression patients high tumor was significantly higher than that for Aurora-A negative or that for diffuse cytoplasmic Aurora-A expression patients (PIs: 63.5, 49.2, and 41.7, respectively; P < .001) (Table 2). There was no significant difference in the mean IMVD or in the mean AI according to the status of Aurora-A expression; there was no significant correlation between Aurora-A expression status and p53 status (Table 2). Table 2.Correlation between Aurora expression and other biomarkersAurora expressionP valueNegativePositiveDiffuse cytoplasmicPerimembraneIntratumoral microvessel density (IMVD)*191.2 +/- 16.3174.7 +/- 8.9167.6 +/- 14.6.584Proliferative index (PI) (%)49.2 +/- 4.841.7 +/- 2.563.5 +/- 3.8<.001Apoptotic index (AI) (/1000 tumor cells)13.5 +/- 3.220.5 +/- 2.015.9 +/- 2.5.154p53-status: Aberrant expression (+)12/31 (38.7%)55/124 (44.4%)15/34 (44.1%).848Values were shown as the mean +/- standard error (SE).* Evaluated with an anti-CD34 antibody.
###end p 34
###begin p 35
Correlation between Aurora expression and other biomarkers
###end p 35
###begin p 36
Values were shown as the mean +/- standard error (SE).
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* Evaluated with an anti-CD34 antibody.
###end p 37
###begin title 38
Expression of Aurora-A and Postoperative Survival
###end title 38
###begin p 39
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 299 307 299 307 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3.</label>
###xml 307 398 307 398 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients</p>
###xml 307 398 307 398 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients</p></caption>
###xml 398 398 398 398 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4"/>
###xml 398 422 398 422 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">5-year survival rate (%)</th>
###xml 422 423 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 422 429 422 429 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="4"><italic>P</italic> value</th>
###xml 398 429 398 429 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="4"/><th align="left" colspan="3">5-year survival rate (%)</th><th align="left" rowspan="4"><italic>P</italic> value</th></tr>
###xml 429 446 429 446 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">AURORA expression</th>
###xml 429 446 429 446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="3">AURORA expression</th></tr>
###xml 446 454 446 454 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Negative</th>
###xml 454 462 454 462 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Positive</th>
###xml 446 462 446 462 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr>
###xml 462 481 462 481 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diffuse cytoplasmic</th>
###xml 481 493 481 493 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Perimembrane</th>
###xml 462 493 462 493 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr>
###xml 398 493 398 493 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="4"/><th align="left" colspan="3">5-year survival rate (%)</th><th align="left" rowspan="4"><italic>P</italic> value</th></tr><tr><th align="left" colspan="3">AURORA expression</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead>
###xml 493 505 493 505 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All patients</td>
###xml 505 510 505 510 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67.8%</td>
###xml 510 515 510 515 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">66.7%</td>
###xml 515 520 515 520 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47.6%</td>
###xml 520 524 520 524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.033</td>
###xml 493 524 493 524 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">All patients</td><td char="." align="char">67.8%</td><td char="." align="char">66.7%</td><td char="." align="char">47.6%</td><td char="." align="char">.033</td></tr>
###xml 524 556 524 556 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Subset analysis, histologic type</td>
###xml 524 556 524 556 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Subset analysis, histologic type</td></tr>
###xml 556 578 556 578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td>
###xml 578 583 578 583 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">75.0%</td>
###xml 583 588 583 588 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">74.2%</td>
###xml 588 593 588 593 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">34.5%</td>
###xml 593 597 593 597 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.007</td>
###xml 556 597 556 597 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td char="." align="char">75.0%</td><td char="." align="char">74.2%</td><td char="." align="char">34.5%</td><td char="." align="char">.007</td></tr>
###xml 597 611 597 611 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td>
###xml 611 616 611 616 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">64.2%</td>
###xml 616 621 616 621 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60.8%</td>
###xml 621 626 621 626 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62.5%</td>
###xml 626 630 626 630 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.894</td>
###xml 597 630 597 630 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td char="." align="char">64.2%</td><td char="." align="char">60.8%</td><td char="." align="char">62.5%</td><td char="." align="char">.894</td></tr>
###xml 630 650 630 650 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">Pathologic (p-)stage</td>
###xml 630 650 630 650 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left" colspan="5">Pathologic (p-)stage</td></tr>
###xml 650 655 650 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;I</td>
###xml 655 660 655 660 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">91.7%</td>
###xml 660 665 660 665 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">72.9%</td>
###xml 665 670 665 670 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">58.3%</td>
###xml 670 674 670 674 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.098</td>
###xml 650 674 650 674 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="char">91.7%</td><td char="." align="char">72.9%</td><td char="." align="char">58.3%</td><td char="." align="char">.098</td></tr>
###xml 674 680 674 680 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;II</td>
###xml 680 685 680 685 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">75.0%</td>
###xml 685 690 685 690 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">68.6%</td>
###xml 690 695 690 695 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.1%</td>
###xml 695 699 695 699 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.579</td>
###xml 674 699 674 699 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;II</td><td char="." align="char">75.0%</td><td char="." align="char">68.6%</td><td char="." align="char">57.1%</td><td char="." align="char">.579</td></tr>
###xml 699 707 699 707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#160;&#160;&#160;&#160;IIIA</td>
###xml 707 712 707 712 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50.4%</td>
###xml 712 717 712 717 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50.9%</td>
###xml 717 722 717 722 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28.9%</td>
###xml 722 726 722 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.088</td>
###xml 699 726 699 726 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td char="." align="char">50.4%</td><td char="." align="char">50.9%</td><td char="." align="char">28.9%</td><td char="." align="char">.088</td></tr>
###xml 493 726 493 726 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">All patients</td><td char="." align="char">67.8%</td><td char="." align="char">66.7%</td><td char="." align="char">47.6%</td><td char="." align="char">.033</td></tr><tr><td align="left" colspan="5">Subset analysis, histologic type</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td char="." align="char">75.0%</td><td char="." align="char">74.2%</td><td char="." align="char">34.5%</td><td char="." align="char">.007</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td char="." align="char">64.2%</td><td char="." align="char">60.8%</td><td char="." align="char">62.5%</td><td char="." align="char">.894</td></tr><tr><td align="left" colspan="5">Pathologic (p-)stage</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="char">91.7%</td><td char="." align="char">72.9%</td><td char="." align="char">58.3%</td><td char="." align="char">.098</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td char="." align="char">75.0%</td><td char="." align="char">68.6%</td><td char="." align="char">57.1%</td><td char="." align="char">.579</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td char="." align="char">50.4%</td><td char="." align="char">50.9%</td><td char="." align="char">28.9%</td><td char="." align="char">.088</td></tr></tbody>
###xml 398 726 398 726 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="4"/><th align="left" colspan="3">5-year survival rate (%)</th><th align="left" rowspan="4"><italic>P</italic> value</th></tr><tr><th align="left" colspan="3">AURORA expression</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">All patients</td><td char="." align="char">67.8%</td><td char="." align="char">66.7%</td><td char="." align="char">47.6%</td><td char="." align="char">.033</td></tr><tr><td align="left" colspan="5">Subset analysis, histologic type</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td char="." align="char">75.0%</td><td char="." align="char">74.2%</td><td char="." align="char">34.5%</td><td char="." align="char">.007</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td char="." align="char">64.2%</td><td char="." align="char">60.8%</td><td char="." align="char">62.5%</td><td char="." align="char">.894</td></tr><tr><td align="left" colspan="5">Pathologic (p-)stage</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="char">91.7%</td><td char="." align="char">72.9%</td><td char="." align="char">58.3%</td><td char="." align="char">.098</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td char="." align="char">75.0%</td><td char="." align="char">68.6%</td><td char="." align="char">57.1%</td><td char="." align="char">.579</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td char="." align="char">50.4%</td><td char="." align="char">50.9%</td><td char="." align="char">28.9%</td><td char="." align="char">.088</td></tr></tbody></table>
###xml 299 726 299 726 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3.</label><caption><p textid="40">Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="4"/><th align="left" colspan="3">5-year survival rate (%)</th><th align="left" rowspan="4"><italic>P</italic> value</th></tr><tr><th align="left" colspan="3">AURORA expression</th></tr><tr><th align="left" rowspan="2">Negative</th><th align="left" colspan="2">Positive</th></tr><tr><th align="left">Diffuse cytoplasmic</th><th align="left">Perimembrane</th></tr></thead><tbody><tr><td align="left">All patients</td><td char="." align="char">67.8%</td><td char="." align="char">66.7%</td><td char="." align="char">47.6%</td><td char="." align="char">.033</td></tr><tr><td align="left" colspan="5">Subset analysis, histologic type</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Squamous cell (Sq)</td><td char="." align="char">75.0%</td><td char="." align="char">74.2%</td><td char="." align="char">34.5%</td><td char="." align="char">.007</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;Adeno (Ad)</td><td char="." align="char">64.2%</td><td char="." align="char">60.8%</td><td char="." align="char">62.5%</td><td char="." align="char">.894</td></tr><tr><td align="left" colspan="5">Pathologic (p-)stage</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;I</td><td char="." align="char">91.7%</td><td char="." align="char">72.9%</td><td char="." align="char">58.3%</td><td char="." align="char">.098</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;II</td><td char="." align="char">75.0%</td><td char="." align="char">68.6%</td><td char="." align="char">57.1%</td><td char="." align="char">.579</td></tr><tr><td align="left">&#160;&#160;&#160;&#160;IIIA</td><td char="." align="char">50.4%</td><td char="." align="char">50.9%</td><td char="." align="char">28.9%</td><td char="." align="char">.088</td></tr></tbody></table></table-wrap>
###xml 726 733 726 733 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2.</label>
###xml 733 906 733 906 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Survival curves of patients who underwent complete resection for pathologic (p-) stage I&#8211;IIIA non-small-cell lung cancer. Comparison according to Aurora-A expression status.</p>
###xml 733 906 733 906 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Survival curves of patients who underwent complete resection for pathologic (p-) stage I&#8211;IIIA non-small-cell lung cancer. Comparison according to Aurora-A expression status.</p></caption>
###xml 906 906 906 906 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10434_2007_9653_Fig2_HTML" id="MO2"/>
###xml 726 906 726 906 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2.</label><caption><p textid="41">Survival curves of patients who underwent complete resection for pathologic (p-) stage I&#8211;IIIA non-small-cell lung cancer. Comparison according to Aurora-A expression status.</p></caption><graphic position="anchor" xlink:href="10434_2007_9653_Fig2_HTML" id="MO2"/></fig>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 752 760 <span type="species:ncbi:9606">patients</span>
For all 189 patients, 5-year survival rates of Aurora-A negative patients, diffuse cytoplasmic Aurora-A patients, and perimembrane Aurora-A patients were 67.8%, 66.7%, and 47.6%, respectively; perimembrane Aurora-A patients showed the poorest postoperative survival (P = .033) (Table 3 and Fig. 2). Table 3.Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients5-year survival rate (%)P valueAURORA expressionNegativePositiveDiffuse cytoplasmicPerimembraneAll patients67.8%66.7%47.6%.033Subset analysis, histologic type    Squamous cell (Sq)75.0%74.2%34.5%.007    Adeno (Ad)64.2%60.8%62.5%.894Pathologic (p-)stage    I91.7%72.9%58.3%.098    II75.0%68.6%57.1%.579    IIIA50.4%50.9%28.9%.088Fig. 2.Survival curves of patients who underwent complete resection for pathologic (p-) stage I-IIIA non-small-cell lung cancer. Comparison according to Aurora-A expression status.
###end p 39
###begin p 40
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients
###end p 40
###begin p 41
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Survival curves of patients who underwent complete resection for pathologic (p-) stage I-IIIA non-small-cell lung cancer. Comparison according to Aurora-A expression status.
###end p 41
###begin p 42
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
Subset analyses revealed that perimembrane Aurora-A expression was a significant factor to predict a poor prognosis in squamous cell carcinoma patients, not in adenocarcinoma patients (P = .007 and P = .894, respectively) (Table 3).
###end p 42
###begin p 43
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 221 228 221 228 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 228 305 228 305 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Multivariate analysis of prognostic factors (Cox&#8217;s proportional hazard model)</p>
###xml 228 305 228 305 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Multivariate analysis of prognostic factors (Cox&#8217;s proportional hazard model)</p></caption>
###xml 305 312 305 312 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Factors</th>
###xml 312 316 312 316 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Beta</th>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 316 323 316 323 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P</italic> value</th>
###xml 323 361 323 361 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Hazard ratio (95% confidence interval)</th>
###xml 305 361 305 361 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Factors</th><th align="left">Beta</th><th align="left"><italic>P</italic> value</th><th align="left">Hazard ratio (95% confidence interval)</th></tr>
###xml 305 361 305 361 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Factors</th><th align="left">Beta</th><th align="left"><italic>P</italic> value</th><th align="left">Hazard ratio (95% confidence interval)</th></tr></thead>
###xml 361 381 361 381 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gender (male/female)</td>
###xml 381 387 381 387 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.539</td>
###xml 387 391 387 391 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.096</td>
###xml 391 410 391 410 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.583 (0.309&#8211;1.101)</td>
###xml 361 410 361 410 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Gender (male/female)</td><td char="." align="char">&#8722;0.539</td><td char="." align="char">.096</td><td char="." align="char">0.583 (0.309&#8211;1.101)</td></tr>
###xml 410 413 410 413 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age</td>
###xml 413 418 413 418 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.006</td>
###xml 418 422 418 422 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.714</td>
###xml 422 441 422 441 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.006 (0.977&#8211;1.035)</td>
###xml 410 441 410 441 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Age</td><td char="." align="char">0.006</td><td char="." align="char">.714</td><td char="." align="char">1.006 (0.977&#8211;1.035)</td></tr>
###xml 441 467 441 467 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Performance status (0/1/2)</td>
###xml 467 472 467 472 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.183</td>
###xml 472 476 472 476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.571</td>
###xml 476 495 476 495 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.201 (0.637&#8211;2.264)</td>
###xml 441 495 441 495 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Performance status (0/1/2)</td><td char="." align="char">0.183</td><td char="." align="char">.571</td><td char="." align="char">1.201 (0.637&#8211;2.264)</td></tr>
###xml 495 545 495 545 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Histologic type (Nonadenocarcinoma/adenocarcinoma)</td>
###xml 545 551 545 551 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.050</td>
###xml 551 555 551 555 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.162</td>
###xml 555 574 555 574 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.951 (0.887&#8211;1.020)</td>
###xml 495 574 495 574 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Histologic type (Nonadenocarcinoma/adenocarcinoma)</td><td char="." align="char">&#8722;0.050</td><td char="." align="char">.162</td><td char="." align="char">0.951 (0.887&#8211;1.020)</td></tr>
###xml 574 602 574 602 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pathologic stage (I/II/IIIa)</td>
###xml 602 607 602 607 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.551</td>
###xml 607 611 607 611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.001</td>
###xml 611 630 611 630 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.734 (1.311&#8211;2.295)</td>
###xml 574 630 574 630 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Pathologic stage (I/II/IIIa)</td><td char="." align="char">0.551</td><td char="." align="char">.001</td><td char="." align="char">1.734 (1.311&#8211;2.295)</td></tr>
###xml 630 669 630 669 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Perimembrane Aurora expression (No/Yes)</td>
###xml 669 675 669 675 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8722;0.362</td>
###xml 675 679 675 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">.032</td>
###xml 679 698 679 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.343 (0.169&#8211;0.699)</td>
###xml 630 698 630 698 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Perimembrane Aurora expression (No/Yes)</td><td char="." align="char">&#8722;0.362</td><td char="." align="char">.032</td><td char="." align="char">0.343 (0.169&#8211;0.699)</td></tr>
###xml 361 698 361 698 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Gender (male/female)</td><td char="." align="char">&#8722;0.539</td><td char="." align="char">.096</td><td char="." align="char">0.583 (0.309&#8211;1.101)</td></tr><tr><td align="left">Age</td><td char="." align="char">0.006</td><td char="." align="char">.714</td><td char="." align="char">1.006 (0.977&#8211;1.035)</td></tr><tr><td align="left">Performance status (0/1/2)</td><td char="." align="char">0.183</td><td char="." align="char">.571</td><td char="." align="char">1.201 (0.637&#8211;2.264)</td></tr><tr><td align="left">Histologic type (Nonadenocarcinoma/adenocarcinoma)</td><td char="." align="char">&#8722;0.050</td><td char="." align="char">.162</td><td char="." align="char">0.951 (0.887&#8211;1.020)</td></tr><tr><td align="left">Pathologic stage (I/II/IIIa)</td><td char="." align="char">0.551</td><td char="." align="char">.001</td><td char="." align="char">1.734 (1.311&#8211;2.295)</td></tr><tr><td align="left">Perimembrane Aurora expression (No/Yes)</td><td char="." align="char">&#8722;0.362</td><td char="." align="char">.032</td><td char="." align="char">0.343 (0.169&#8211;0.699)</td></tr></tbody>
###xml 305 698 305 698 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Factors</th><th align="left">Beta</th><th align="left"><italic>P</italic> value</th><th align="left">Hazard ratio (95% confidence interval)</th></tr></thead><tbody><tr><td align="left">Gender (male/female)</td><td char="." align="char">&#8722;0.539</td><td char="." align="char">.096</td><td char="." align="char">0.583 (0.309&#8211;1.101)</td></tr><tr><td align="left">Age</td><td char="." align="char">0.006</td><td char="." align="char">.714</td><td char="." align="char">1.006 (0.977&#8211;1.035)</td></tr><tr><td align="left">Performance status (0/1/2)</td><td char="." align="char">0.183</td><td char="." align="char">.571</td><td char="." align="char">1.201 (0.637&#8211;2.264)</td></tr><tr><td align="left">Histologic type (Nonadenocarcinoma/adenocarcinoma)</td><td char="." align="char">&#8722;0.050</td><td char="." align="char">.162</td><td char="." align="char">0.951 (0.887&#8211;1.020)</td></tr><tr><td align="left">Pathologic stage (I/II/IIIa)</td><td char="." align="char">0.551</td><td char="." align="char">.001</td><td char="." align="char">1.734 (1.311&#8211;2.295)</td></tr><tr><td align="left">Perimembrane Aurora expression (No/Yes)</td><td char="." align="char">&#8722;0.362</td><td char="." align="char">.032</td><td char="." align="char">0.343 (0.169&#8211;0.699)</td></tr></tbody></table>
###xml 221 698 221 698 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="44">Multivariate analysis of prognostic factors (Cox&#8217;s proportional hazard model)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Factors</th><th align="left">Beta</th><th align="left"><italic>P</italic> value</th><th align="left">Hazard ratio (95% confidence interval)</th></tr></thead><tbody><tr><td align="left">Gender (male/female)</td><td char="." align="char">&#8722;0.539</td><td char="." align="char">.096</td><td char="." align="char">0.583 (0.309&#8211;1.101)</td></tr><tr><td align="left">Age</td><td char="." align="char">0.006</td><td char="." align="char">.714</td><td char="." align="char">1.006 (0.977&#8211;1.035)</td></tr><tr><td align="left">Performance status (0/1/2)</td><td char="." align="char">0.183</td><td char="." align="char">.571</td><td char="." align="char">1.201 (0.637&#8211;2.264)</td></tr><tr><td align="left">Histologic type (Nonadenocarcinoma/adenocarcinoma)</td><td char="." align="char">&#8722;0.050</td><td char="." align="char">.162</td><td char="." align="char">0.951 (0.887&#8211;1.020)</td></tr><tr><td align="left">Pathologic stage (I/II/IIIa)</td><td char="." align="char">0.551</td><td char="." align="char">.001</td><td char="." align="char">1.734 (1.311&#8211;2.295)</td></tr><tr><td align="left">Perimembrane Aurora expression (No/Yes)</td><td char="." align="char">&#8722;0.362</td><td char="." align="char">.032</td><td char="." align="char">0.343 (0.169&#8211;0.699)</td></tr></tbody></table></table-wrap>
A multivariate analysis of prognosis factors using a Cox proportional hazard model confirmed that perimembrane Aurora-A expression was an independent and significant factor to predict a poor prognosis in NSCLC (Table 4). Table 4Multivariate analysis of prognostic factors (Cox's proportional hazard model)FactorsBetaP valueHazard ratio (95% confidence interval)Gender (male/female)-0.539.0960.583 (0.309-1.101)Age0.006.7141.006 (0.977-1.035)Performance status (0/1/2)0.183.5711.201 (0.637-2.264)Histologic type (Nonadenocarcinoma/adenocarcinoma)-0.050.1620.951 (0.887-1.020)Pathologic stage (I/II/IIIa)0.551.0011.734 (1.311-2.295)Perimembrane Aurora expression (No/Yes)-0.362.0320.343 (0.169-0.699)
###end p 43
###begin p 44
Multivariate analysis of prognostic factors (Cox's proportional hazard model)
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 765 766 765 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1262 1264 1262 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1264 1272 1264 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aurora-A</italic>
###xml 1333 1341 1333 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aurora-A</italic>
###xml 1430 1432 1430 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1557 1559 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
The present study is the first clinical study on Aurora-A expression in NSCLC and has revealed the clinical significance as follows: (1) positive Aurora-A expression is exclusively observed in tumor cells, not in normal cells; (2) there are two Aurora-A expression patterns, diffuse cytoplasmic staining and perimembrane staining; (3) perimembrane staining is significantly correlated to higher p-stage and higher proliferative activity; and (4) perimembrane staining is a significant and independent factor to predict a poor prognosis, especially in squamous cell carcinoma patients. As mentioned in the introduction section, previous experimental and clinical studies have demonstrated that Aurora-A is overexpressed and upregulated in tumor cells and/or tissues,8-20,22,26 which is also true in NSCLC as demonstrated in the present study. The centrosomes play important roles in the maintenance of genomic instability by establishing bipolar spindles during mitosis and by ensuring equal segregation of replicated chromosome into two daughter cells.27 Aurora-A is involved in normal centrosome functions, and its abnormalities such as gene amplification and overexpression may lead to centrosome function disorder, chromosomal instability, and carcinogenesis.26Aurora-A gene amplification usually contributes to overexpression of Aurora-A gene and Aurora-A protein, but also common is overexpression without gene amplification.22 These results may suggest that Aurora-A expression is regulated not only by gene amplification but also by other mechanisms.22 In the present study, only Aurora-A protein expression was assessed immunohistochemically, and comparative study of overexpression and amplification should be conducted in future.
###end p 46
###begin p 47
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 422 424 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 990 991 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 582 590 <span type="species:ncbi:9606">patients</span>
In previous clinical studies on Aurora-A expression assessed with IHS, Aurora-A expression was classified simply into negative or positive, and its clinical significance was examined.13,15-18,20 Some studies showed a significantly positive correlation between Aurora-A overexpression and aggressive tumor behavior such as poor differentiation and nodal metastasis,15,16,20 but others showed no17 or an inverse correlation.18 In addition, among three studies where prognostic significance of Aurora-A overexpression was assessed, two studies showed a significantly poor prognosis in patients with Aurora-A overexpression13,16 and one failed to show.20 These conflicting results on clinical significance of Aurora-A expression status might be partly due to the evaluation system. In fact, there was no difference in the proliferative activity as represented as PI or in the prognosis between negative Aurora-A tumors and diffuse cytoplasmic Aurora-A tumors in the present study (Tables 2 and 3); when perimembrane Aurora-A expression was separated and analyzed, tumors with perimembrane Aurora-A expression showed an aggressive tumor phenotype correlated with a higher PI and a poor prognosis. The biochemical implication of perimembrane Aurora-A expression is unknown, staining patterns should be taken into consideration in evaluation of Aurora-A expression status in clinical samples.
###end p 47
###begin p 48
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
Another reason for conflicting results of clinical significance of Aurora-A expression status might be difference in the histologic type. Two clinical studies on esophageal squamous cell carcinoma showed that Aurora-A overexpression was significantly correlated with aggressive tumor behavior.15,16 In contrast, two clinical studies on adenocarcinoma, one on pancreatic cancer17 and one on breast cancer,20 failed to show a significant correlation between Aurora-A status and tumor differentiation or prognosis. In fact, a subset analysis according to histologic types in the present study showed that perimembrane Aurora-A expression was a significant factor to predict a poor prognosis in lung squamous cell carcinoma, but not in lung adenocarcinoma (Table 3). These results may suggest that clinical impact of Aurora-A expression status is enhanced in squamous cell carcinoma and reduced in adenocarcinoma. Further clinical studies on a variety of malignant tumors will give some answers to the issue.
###end p 48
###begin p 49
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1037 1039 1037 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 1330 1333 1330 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
We analyzed correlations between Aurora-A status and other biomarkers such as proliferative activity and p53 status. There has been no clinical study where Aurora-A status is assessed in correlation with proliferative activity. Considering experimental results that Aurora-A is a centrosome-associated kinase that contributes to regulation of cell mitosis,8,26 Aurora-A expression status may be correlated with proliferative activity in clinical samples as shown in the present study (Table 2). However, it remains unknown why a specific Aurora-A expression pattern, the perimembrane expression, is correlated with higher proliferative activity. Experimental studies have also suggested an interaction between Aurora-A and p53,28-30 suggesting that the p53 inhibit oncogenic activity of Aurora-A28 and that Aurora-A, especially when overexpressed, inactivate tumor-suppressor activity of p53.29,30 One clinical study also documented that Aurora-A overexpression was significantly correlated with p53 mutation in hepatocellular carcinoma.22 These results strongly suggest that Aurora-A in concert with p53 contributes to the development and progression of malignant tumors. In the present study, we failed to show a significant correlation between Aurora-A expression status and p53 status as assessed with IHS. In a future study, p53 gene mutation status in correlation with Aurora-A expression should be examined.
###end p 49
###begin p 50
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aurora-A</italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 608 616 608 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Aurora-A</italic>
More recently, increasing studies on Aurora-A gene polymorphisms and risk of malignant tumors have been reported.31-36 Two common single nucleotide polymorphisms in the coding regions are 91T->A transversion and 169G->A transversion, which result in phenylalanine/isoleucine substitution at amino acid 31 (F31I) and valine/isoleucine substitution at amino acid 57 (V57I), respectively. Several studies have shown such polymorphisms are associated with increased risk of occurrence of a variety of malignant tumors including esophageal,31,35 ovarian,32 and breast33,34 cancers. In future, correlation between Aurora-A polymorphism and risk of development of primary lung cancer should be investigated. In conclusion, Aurora-A expression status was a significant prognostic factor in correlation with proliferative activity in NSCLC. To confirm the clinical significance, future prospective studies should be conducted.
###end p 50
###begin title 51
Acknowledgment
###end title 51
###begin p 52
We thank Miss Seiko Sakai for helpful preparation of the manuscript.
###end p 52
###begin p 53
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Revisions in the international system for lung cancer
###end article-title 55
###begin article-title 56
Prognosis and survival in resected lung carcinoma based on the new international staging system
###end article-title 56
###begin article-title 57
Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend
###end article-title 57
###begin article-title 58
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
###end article-title 58
###begin article-title 59
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
###end article-title 59
###begin article-title 60
Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles
###end article-title 60
###begin article-title 61
###xml 15 25 <span type="species:ncbi:7227">Drosophila</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
###end article-title 61
###begin article-title 62
Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
###end article-title 62
###begin article-title 63
###xml 76 79 <span type="species:ncbi:10116">rat</span>
Centrosome amplification and overexpression of Aurora A are early events in rat mammary carcinogenesis
###end article-title 63
###begin article-title 64
Function and regulation of Aurora/Ip11p kinase family in cell division
###end article-title 64
###begin article-title 65
Aurora kinases
###end article-title 65
###begin article-title 66
###xml 45 50 <span type="species:ncbi:9606">human</span>
Overexpression and amplification of STK15 in human gliomas
###end article-title 66
###begin article-title 67
Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival
###end article-title 67
###begin article-title 68
Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation
###end article-title 68
###begin article-title 69
###xml 67 72 <span type="species:ncbi:9606">human</span>
Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma
###end article-title 69
###begin article-title 70
###xml 63 68 <span type="species:ncbi:9606">human</span>
The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma
###end article-title 70
###begin article-title 71
###xml 58 63 <span type="species:ncbi:9606">human</span>
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer
###end article-title 71
###begin article-title 72
###xml 69 74 <span type="species:ncbi:9606">human</span>
Activation and over expression of centrosome kinase BTAK/Aurora-A in human ovarian cancer
###end article-title 72
###begin article-title 73
###xml 93 98 <span type="species:ncbi:9606">human</span>
Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers
###end article-title 73
###begin article-title 74
STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis
###end article-title 74
###begin article-title 75
###xml 57 62 <span type="species:ncbi:9606">human</span>
Amplification/overexpression of a mitotic kinase gene in human bladder cancer
###end article-title 75
###begin article-title 76
Over expression and amplification of Aurora-A in hepatocellular carcinoma
###end article-title 76
###begin article-title 77
Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer
###end article-title 77
###begin article-title 78
p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer
###end article-title 78
###begin article-title 79
Evaluation of angiogenesis in non-small cell lung cancer : comparison between anti-CD34 antibody and anti-CD105 antibody
###end article-title 79
###begin article-title 80
###xml 15 25 <span type="species:ncbi:7227">Drosophila</span>
###xml 70 75 <span type="species:ncbi:9606">human</span>
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
###end article-title 80
###begin article-title 81
Amorphous no longer: the centrosome comes into focus
###end article-title 81
###begin article-title 82
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function
###end article-title 82
###begin article-title 83
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215
###end article-title 83
###begin article-title 84
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
###end article-title 84
###begin article-title 85
Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma
###end article-title 85
###begin article-title 86
STK15 polymorphisms and association with risk of invasive ovarian cancer
###end article-title 86
###begin article-title 87
STK15 polymorphism and breast cancer risk in a population-based study
###end article-title 87
###begin article-title 88
Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma
###end article-title 88
###begin article-title 89
Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk
###end article-title 89
###begin article-title 90
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types
###end article-title 90

